Early-Term Delivery May Not Up Adverse Neonatal Outcomes

Share this content:
Early-Term Delivery May Not Up Adverse Neonatal Outcomes
Early-Term Delivery May Not Up Adverse Neonatal Outcomes

MONDAY, March 14, 2016 (HealthDay News) -- Elective early-term deliveries may not be associated with increased risk of adverse neonatal outcomes, according to a study published in the April issue of Obstetrics & Gynecology.

Jason L. Salemi, Ph.D., M.P.H., from the Baylor College of Medicine in Houston, and colleagues conducted a population-based retrospective cohort study involving 675,302 singleton infants born at 37 to 44 weeks of gestation from 2005 to 2009. The population was categorized into groups based on timing and reason for delivery initiation, with four subtypes of deliveries at 37 to 38 weeks of gestation and a comparison group of expectantly managed infants delivered at gestational week 39 to 40.

The researchers found that infants delivered after elective induction at 37 to 38 weeks of gestation did not have increased odds of neonatal respiratory morbidity, sepsis, or neonatal intensive care unit admission, but they did have slightly elevated odds of feeding difficulty compared with infants managed expectantly and delivered at 39 to 40 weeks of gestation (odds ratio, 1.18). The odds of adverse outcomes were increased by 13 to 66 percent for infants delivered by elective cesarean at 37 to 38 weeks. Early inductions and early cesarean deliveries had similar survival experiences compared with the expectant management group.

"The issues that surround the timing and reasons for delivery initiation are complicated and each pregnancy unique," the authors write. "This study cautions against a general avoidance of all elective early-term deliveries."

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »